Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs